Coherus Chief: FTC Must Probe Originators’ Anti-Competitive Tactics
Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.
You may also be interested in...
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.
Coherus’ manufacturing process for its Udenyca pegfilgrastim biosimilar does not infringe a US purification patent held by Amgen, the US Court of Appeals has confirmed.
US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.